Status:
ENROLLING_BY_INVITATION
Evaluation of the Efficacy of Transcranial Direct Current Stimulation in Reducing Fatigue and Improving Quality of Life in Patients With Multiple Sclerosis: A Randomized Clinical Trial
Lead Sponsor:
European University of Madrid
Conditions:
Multiple Sclerosis, MS
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
The goal of this clinical trial is to evaluate whether the application of three 2-week cycles of tDCS combined with motor therapy is more effective in reducing fatigue in adult patients with multiple ...
Eligibility Criteria
Inclusion
- Patients with multiple sclerosis defined according to the McDonald criteria (2017 revised version).
- Age between 18 and 75 years.
- No relapse in the last 2 months.
- Fatigue experienced in the last 6 months, according to the Fatigue Severity Scale (FSS \> 4).
Exclusion
- Patients who have not had stable pharmacological treatment in the last month.
- Patients with contraindications to the use of tDCS, such as: defibrillator, pacemaker, brain stimulator, implanted intracranial metals, skull fractures or fissures, damaged skin or recent scars, epilepsy, pregnancy.
- Patients who are undergoing or need to undergo immunosuppressive treatment for MS with Ocrelizumab, Rituximab, Lemtrada, or Mavenclad one week before or during the application of tDCS.
- Patients with cognitive difficulties that prevent them from understanding the applied scales.
- Patients who experience adverse effects from tDCS treatment.
- Inability to remain in the study and complete the third cycle and/or the V3 assessment.
Key Trial Info
Start Date :
February 20 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 31 2025
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT06873464
Start Date
February 20 2025
End Date
August 31 2025
Last Update
March 12 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fundación Esclerosis Multiple Madrid
Madrid, Spain, 28029